Program
Anti-STEAP2/Anti-CD3/Anti-CD8 Trispecific Antibody AZD6621
Its studies are mostly in Prostatic Neoplasms, led by AstraZeneca.
Furthest: phase 2, since Jul 11, 20251 company-led study, 1 open or runningNext primary completion: Mar 29, 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 11 open or running | phase 2since Jul 11, 2025 | Jul 11, 2025 | Mar 29, 2029phase 2 · NCT07192614 |
- Named in AstraZeneca’s own pipeline as
AZD6621
, phase 1, as of Oct 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 11, 2025First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT07192614 · 52 planned · United States, Belgium, Canada and more
Ahead
- Mar 29, 2029Primary completion: phase 2 study in Prostatic NeoplasmsNCT07192614
TargetBeta
“A trispecific T-cell engager and antibody targeting the tumor-associated antigen (TAA) metalloreductase six-transmembrane epithelial antigen of prostate-2 (STEAP2; STAMP1), and the T-cell surface antigens CD3 and CD8, with potential immunostimulating and antineoplastic activities. Upon administra…”NCIt, read by Claude
“A trispecific T-cell engager and antibody targeting the tumor-associated antigen (TAA) metalloreductase six-transmembrane epithelial antigen of prostate-2 (STEAP2; STAMP1), and the T-cell surface antigens CD3 and CD8, ”NCIt, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07192614Prostatic Neoplasms · United States, Belgium, Canada and more | 2 | Recruiting | Mar 29, 2029 | 52 |
How it is read
Names in the registry
- “AZD6621”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.